Premaitha Health PLC Grant of Share Options (9572U)
October 30 2017 - 5:08AM
UK Regulatory
TIDMNIPT
RNS Number : 9572U
Premaitha Health PLC
30 October 2017
Premaitha Health plc
("Premaitha" or the "Company")
Grant of share options
Manchester, UK - 30 October 2017: Premaitha Health plc (AIM:
NIPT), a leading international molecular diagnostics group focused
on non-invasive prenatal testing ("NIPT"), announces that it has
made a grant of share options.
The Company has today issued 3,825,000 options over ordinary
shares under the Company's Enterprise Management Incentive (EMI)
and unapproved share option schemes to a number of managers and key
staff in lieu of cash bonuses ("New Options").
The New Options are exercisable in three tranches over three
financial years and are subject to certain performance conditions,
with the options being exercisable up to 29 October 2027, at a
price of 10 pence per share.
Following the issue of the New Options, and taking into account
lapsed options, the Company has 40,046,830 shares under option and
a further 86,094,192 shares under warrant. The issued share capital
of the Company comprises 321,218,279 Ordinary Shares of 0.1p
each.
For more information, please contact:
Premaitha Health plc Tel: +44 (0)
161 667 6865
Dr Stephen Little, Chief Executive
Office
Barry Hextall, Chief Financial
Officer
Joanne Cross, Head of Marketing
investors@premaitha.com
Cairn Financial Advisers LLP (Nomad) Tel: +44 (0)
20 7213 0880
Liam Murray / James Caithie
finnCap (Broker) Tel: +44 (0)
20 7220 0500
Adrian Hargrave / Scott Mathieson
(Corporate Finance)
Tony Quirke (Corporate Broking)
Vigo Communications Tel: +44 (0)
20 7830 9701
Ben Simons / Fiona Henson / Antonia
Pollock
premaitha@vigocomms.com
About Premaitha
Premaitha is an international molecular diagnostics group which
uses the latest advances in DNA analysis technology to develop
safer, faster and regulatory approved genetic screening tests. The
Group's primary focus is on non-invasive prenatal tests (NIPT) for
pregnant women - an emerging, multi-billion dollar global
market.
Premaitha's IONA(R) test was launched in 2015 as the first
CE-IVD NIPT test in Europe. It enables laboratories and healthcare
practitioners to offer a complete CE-marked NIPT system in-house.
The IONA(R) test is performed on a maternal blood sample - which
contains traces of fetal DNA - and estimates the risk of a fetus
being affected with Down's syndrome or other genetic
conditions.
Unlike existing prenatal screening methods, due to its high
level of accuracy, the IONA(R) test can significantly reduce the
number of women subjected to unnecessary invasive follow up
diagnostic procedures, such as amniocentesis, which are costly,
resource intensive and carry a risk of miscarriage.
In March 2017, Premaitha acquired Yourgene Bioscience, a
specialist next generation sequencing and bioinformatics company
based in Taiwan, with its own NIPT screening test that operates on
the same Thermo Fisher next-generation sequencing platform as
Premaitha's IONA(R) test. Yourgene brings significant benefits to
the Group through expanded market access in Asia - the world's
fastest growing NIPT market - as well as opportunities for
cross-selling and the ability to jointly develop expanded test
content both within NIPT and beyond.
Premaitha is headquartered in Manchester, England, with Yourgene
offices in Taipei and Singapore. Its shares trade on the AIM market
of the London Stock Exchange (AIM: NIPT). For further information,
please visit www.premaitha.com. Follow us on twitter
@PremaithaHealth.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCOKKDKKBDDQKN
(END) Dow Jones Newswires
October 30, 2017 06:08 ET (10:08 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From May 2023 to May 2024